Last update June 21, 2022
Very Low Risk
It is a dibenzazepine derivative with antiepileptic and psychotropic properties. It is used in the treatment of certain epilepsies, trigeminal neuralgia, multiple sclerosis pain, and bipolar disorder. Oral administration 2 to 4 times a day.
It is excreted in breast milk in small amount. (Kacirova 2021, Antonucci 2018, Lopes 2012, Zhao 2010, Shimoyama 2000, Brent 1998, Merlob 1992, Meyer 1988, Froescher 1984, Kuhnz 1983, Kok 1982, Niebyl 1979, Kaneko 1979, Pynnönen 1977 y 1975)
Most infants do not have short-term or long-term clinical or developmental problems (Vajda 2014, Meador 2014 & 2010, Veiby 2013, Johannessen 2005, Wisner 1998, Ito 1993, Niebyl 1979, Pynnönen 1977), although isolated cases of drowsiness, poor feeding, and transient liver dysfunction with cholestasis have been reported. (Antonucci 2018, Frey 2002, Merlob 1992, Frey 1990, Kuhnz 1983)
Plasma levels in the infants were between 5% and 40% of the corresponding maternal levels and always below the lower limit of the usual therapeutic range (Mercadé 2012: 4-12 mg/L) for carbamazepine. (Kacirova 2021, Birnbaum 2020, Antonucci 2018, Grover 2015, Wisner 1998, Merlob 1992, Kuhnz 1983, Kok 1982, Pynnönen 1977 y 1975)
One case of Deprivation Syndrome has been reported after sudden discontinuation of medication. (Knott 1987)
Several medical societies and expert authors consider the use of this medication possible during breastfeeding (Hale, LactMed, Uguz 2021, Crettenand 2018, Briggs 2015, Schaefer 2015, Davanzo 2013, Rowe 2013, Mintzer 2011, O'Connor 2009, Harden 2009, Sharma 2009, Even 2006, Pack 2006, Pennell 2006, O'Brien 2005, Bar-Oz 2000, Hägg 2000). The American Academy of Pediatrics rates it as usually compatible with Breastfeeding (AAP 2001). Eleventh WHO Model List of Essential Drugs 2002: Compatible with breastfeeding. (WHO 2002)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM